PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
190 hedge funds and large institutions have $276M invested in PDL BioPharma, Inc. in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 66 reducing their positions, and 32 closing their positions.
511% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $227K
4% less funds holding
Funds holding: 198 → 190 (-8)
14% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 66
19% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 32
37% less capital invested
Capital invested by funds: $436M → $276M (-$160M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.25M |
| 2 |
Morgan Stanley
New York
|
+$4.13M |
| 3 |
JP Morgan Chase
New York
|
+$3.68M |
| 4 |
ACPU
Arrowgrass Capital Partners (US)
Dover,
Delaware
|
+$2.85M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$8.82M |
| 2 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$7.67M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$3.45M |
| 4 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$3.42M |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$3.11M |
PDLI Hedge Fund Activity: Q4 2016 in Review
190 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2016, worth a combined $276M — down 37% from $436M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of PDLI and 26 opened new positions — a net loss of 6 holders — while 66 trimmed existing stakes and 57 added.
The largest buyer was Citadel Advisors, adding an estimated $8.25M. The largest seller was Armistice Capital, exiting entirely with an estimated $8.82M sold.
- 190 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2016, down from 198 in Q3 2016.
- Funds reported $276M of PDL BioPharma, Inc. stock for Q4 2016, down 37% quarter-over-quarter.
- 26 funds opened new PDL BioPharma, Inc. positions in Q4 2016 and 32 closed out, a net change of -6 holders.
- The largest PDL BioPharma, Inc. buyer in Q4 2016 was Citadel Advisors, an estimated $8.25M added.
- The largest PDL BioPharma, Inc. seller in Q4 2016 was Armistice Capital, an estimated $8.82M sold.
Based on aggregated 13F filings for Q4 2016.